Literature DB >> 25932202

Parameters of prostate cancer at contrast-enhanced ultrasound: correlation with prostate cancer risk.

Guang Xu1, Jian Wu1, Ming-Hua Yao1, Xu-Dong Yao2, Bo Peng2, Qing Wei3, Hui-Xiong Xu4, Rong Wu1.   

Abstract

OBJECTIVE: to investigate the correlation between the parameters of prostate cancer (PCa) at contrast-enhanced ultrasound (CEUS) with PCa risk.
METHODS: 84 patients (68 ± 8 years; range, 33-79 years) who had undergone CEUS were included. All the images were offline analyzed. Parameters (maximum intensity (IMAX), rise time (RT), time to peak (TTP) and mean transit time (mTT)) were recorded and compared with PSA level, Gleason score, clinical stages and PCa risk.
RESULTS: Age was correlated significantly with PCa risk. RT and mTT of outer gland were associated with PCa risk. No significant correlation was found between PSA and CEUS enhancement parameters. Furthermore, with the exception of IMAX of inner gland and IMAX of outer gland, there were no significant differences of enhancement parameters in Gleason score groups and clinical stages groups.
CONCLUSION: The enhancement parameters of PCa at CEUS may be used to predict PCa risk. And it is helpful for the choice of therapeutic options.

Entities:  

Keywords:  Contrast-enhanced ultrasound; prostate cancer; prostate cancer risk

Year:  2015        PMID: 25932202      PMCID: PMC4402849     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  30 in total

1.  Prostate cancer: contrast-enhanced us for detection.

Authors:  E J Halpern; M Rosenberg; L G Gomella
Journal:  Radiology       Date:  2001-04       Impact factor: 11.105

2.  Cancer incidence among patients of the U.S. Veterans Affairs Health Care System.

Authors:  Leah L Zullig; George L Jackson; Raye Anne Dorn; Dawn T Provenzale; Rebecca McNeil; Catherine M Thomas; Michael J Kelley
Journal:  Mil Med       Date:  2012-06       Impact factor: 1.437

Review 3.  Overview of prostate anatomy, histology, and pathology.

Authors:  Christine H Lee; Oluyemi Akin-Olugbade; Alexander Kirschenbaum
Journal:  Endocrinol Metab Clin North Am       Date:  2011-09       Impact factor: 4.741

4.  Evaluation of renal masses with contrast-enhanced ultrasound: initial experience.

Authors:  Scott Gerst; Lucy E Hann; Duan Li; Mithat Gonen; Satish Tickoo; Michael J Sohn; Paul Russo
Journal:  AJR Am J Roentgenol       Date:  2011-10       Impact factor: 3.959

Review 5.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

6.  Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.

Authors:  Monique J Roobol; Heidi A van Vugt; Stacy Loeb; Xiaoye Zhu; Meelan Bul; Chris H Bangma; Arno G L J H van Leenders; Ewout W Steyerberg; Fritz H Schröder
Journal:  Eur Urol       Date:  2011-11-15       Impact factor: 20.096

7.  First results of endocavity evaluation of the microvascularization of malignant prostate tumors using contrast enhanced ultrasound (CEUS) including perfusion analysis: first results.

Authors:  E M Jung; P Wiggermann; C Greis; F Eder; J Ehrich; W Jung; A G Schreyer; C Stroszczynski; R Ganzer
Journal:  Clin Hemorheol Microcirc       Date:  2012       Impact factor: 2.375

8.  Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens.

Authors:  M P Gallee; E Visser-de Jong; J A van der Korput; T H van der Kwast; F J ten Kate; F H Schroeder; J Trapman
Journal:  Urol Res       Date:  1990

9.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.

Authors:  Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

10.  Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?

Authors:  Jennifer R Stark; Sven Perner; Meir J Stampfer; Jennifer A Sinnott; Stephen Finn; Anna S Eisenstein; Jing Ma; Michelangelo Fiorentino; Tobias Kurth; Massimo Loda; Edward L Giovannucci; Mark A Rubin; Lorelei A Mucci
Journal:  J Clin Oncol       Date:  2009-05-11       Impact factor: 44.544

View more
  3 in total

1.  Vascular endothelial growth factor suppresses dendritic cells function of human prostate cancer.

Authors:  Wen-Kun Bai; Wei Zhang; Bing Hu
Journal:  Onco Targets Ther       Date:  2018-03-06       Impact factor: 4.147

2.  Contrast-enhanced transrectal ultrasound can reduce collection of unnecessary biopsies when diagnosing prostate cancer and is predictive of biochemical recurrence following a radical prostatectomy in patients with localized prostate cancer.

Authors:  Hong-Wei Zhao; Jian Li; Jia-Zheng Cao; Juan Lin; Zhu Wang; Jian-Yao Lv; Jin-Huan Wei; Zhen-Hua Chen; Hao-Hua Yao; Yi-Hui Pan; Zhen-Li Gao; Jun-Hang Luo; Wei Chen; Lei Shi; Yong Fang
Journal:  BMC Urol       Date:  2020-07-16       Impact factor: 2.264

3.  Towards reliable diagnostics of prostate cancer via breath.

Authors:  K S Maiti; E Fill; F Strittmatter; Y Volz; R Sroka; A Apolonski
Journal:  Sci Rep       Date:  2021-09-15       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.